Home Blog

0 10

Patent Number: 9,068,199

Grant date: December 31, 1969
Priority date: January 31, 1996
Estimated expiration date: January 31, 2016
Inventor(s): Leboulch; Philippe (Charlestown, MA), Pawliuk; Robert (Medford, MA), Westerman; Karen (Reading, MA)
Assignee(s): Bluebird Bio, Inc. (Cambridge, MA) Massachusetts Institute of Technology (Cambridge, MA)
External link: USPTO website

Abstract:

The invention provides improved compositions and methods for achieving gene therapy in hematopoietic cells and hematopoietic precursor cells, including erythrocytes, erythroid progenitors, and embryonic stem cells. The invention further provides improved gene therapy methods for treating hematopoietic-related disorders. Retroviral gene therapy vectors that are optimized for erythroid specific expression and treatment of hemoglobinopathic conditions are disclosed.

0 9

Patent Number: 9,068,182

Grant date: December 31, 1969
Priority date: January 31, 1996
Estimated expiration date: January 31, 2016
Inventor(s): Deshayes; Sophie (Rampillon, FR), Henry; David (Morigny-Champigny, FR), Hervy; Martial (Thomery, FR)
Assignee(s): Corning Incorporated (Corning, NY)
External link: USPTO website

Abstract:

A cell culture polysaccharide microcarrier includes (1) a cross-linked polysaccharide microcarrier base having a neutral or negative charge at pH 7, and (ii) a polypeptide conjugated to the base. The polypeptide may contain a cell adhesive sequence, such as RGD. Cells cultured with such microcarriers exhibit peptide-specific binding to the microcarriers.

0 10

Patent Number: 9,068,170

Grant date: December 31, 1969
Priority date: January 31, 1996
Estimated expiration date: January 31, 2016
Inventor(s): Zhou; Hongyan (San Diego, CA), Ding; Sheng (Pasadena, CA)
Assignee(s): THE SCRIPPS RESEARCH INSTITUTE (La Jolla, CA)
External link: USPTO website

Abstract:

The present invention provides for methods, compositions, and kits of producing an induced pluripotent stem cell from a mammalian non-pluripotent cell using exogenous transcription factors.

0 12

Patent Number: 9,068,167

Grant date: December 31, 1969
Priority date: January 31, 1996
Estimated expiration date: January 31, 2016
Inventor(s): Kamp; Timothy J. (Madison, WI), Palecek; Sean (Verona, WI), Zhang; Jianhua (Madison, WI), Azarin; Samira (Madison, WI), Lian; Xiaojun (Madison, WI)
Assignee(s): Wisconsin Alumni Research Foundation (Madison, WI)
External link: USPTO website

Abstract:

Methods for culturing the pluripotent stem cells to undergo epithelial-to-mesenchymal transition and for generating high-yield, high-purity cardiomyocyte cultures from pluripotent stem cells are described. Pluripotent stem cells are cultured on a support with an overlaid matrix and, optionally, exposed to one or more factors to induce epithelial-to-mesenchymal transition and cardiogenesis.

0 9

Patent Number: 9,068,166

Grant date: December 31, 1969
Priority date: January 31, 1996
Estimated expiration date: January 31, 2016
Inventor(s): Hwang; Ki Chul (Seoul, KR), Jang; Yang Soo (Seoul, KR), Han; Gyoon Hee (Gyeonggi-do, KR)
Assignee(s): Industry-Academic Cooperation Foundation Yonsei University (Seoul, KR)
External link: USPTO website

Abstract:

Use of a compound of Formula 1 for inducing differentiation of mesenchymal stem cells to chondrocytes, and a pharmaceutical composition for treating a cartilage disease, which includes chondrocytes in which differentiation from mesenchymal stem cells is induced by the compound of Formula 1, are provided. Differentiation of the mesenchymal stem cells treated with the compound of Formula 1 to chondrocytes is specifically induced, and thus the compound can be used to effectively treat a cartilage disease such as arthritis, cartilage damage, and a cartilage defect.

0 8

Patent Number: 9,068,164

Grant date: December 31, 1969
Priority date: January 31, 1996
Estimated expiration date: January 31, 2016
Inventor(s): Abuljadayel; Ilham Saleh (London, GB)
Assignee(s): Tristem Trading (Cyprus) Limited (Nicosia, CY)
External link: USPTO website

Abstract:

Disclosed is a method of preparing an undifferentiated cell. The method includes contacting a more committed cell with an agent that causes the more committed cell to retrodifferentiate into an undifferentiated cell.

0 7

Patent Number: 9,068,163

Grant date: December 31, 1969
Priority date: March 09, 2007
Estimated expiration date: March 09, 2027
Inventor(s): Smith; Gary D. (Ann Arbor, MI), Lahann; Joerg (Ann Arbor, MI), Ding; Jun (Ann Arbor, MI), Nandivada; Himabindu (Ann Arbor, MI)
Assignee(s): The Regents of the University of Michigan (Ann Arbor, MI)
External link: USPTO website

Abstract:

The present invention provides methods and compositions for establishing and maintaining growth of undifferentiated stem cells. In particular, the present invention provides synthetic growth matrices for stem cells, wherein said cells are capable of going through multiple passages while remaining in an undifferentiated state.

0 7

Patent Number: 9,068,162

Grant date: December 31, 1969
Priority date: August 08, 2007
Estimated expiration date: August 08, 2027
Inventor(s): Van Dyke; Mark E. (Winston-Salem, NC)
Assignee(s): Wake Forest University Health Sciences (Winston-Salem, NC)
External link: USPTO website

Abstract:

Provided are keratin compositions useful in cell culture. In some embodiments the keratins are biocompatible, promote cell growth, promote cell adhesion and provide an excellent substrate for cell culture. Keratin compositions described herein may be used as coatings, gels, three-dimensional scaffolds, additives to cell culture media, microcarriers, etc. The keratin substrates may also be used to deliver cells, e.g., for cell therapy applications.

0 7

Patent Number: 9,068,158

Grant date: December 31, 1969
Priority date: August 08, 2007
Estimated expiration date: February 13, 2027
Inventor(s): Rapoport; Uri (Moshav Ben Shemen, IL)
Assignee(s): ASPECT AI LTD. (Moshav Ben Shemen, IL)
External link: USPTO website

Abstract:

The present invention depicts an MRD-based reactor. The MRD-based reactor comprises of a means for containing a flowing media and reacting the same (reactor). The reactor is characterized by a continuous wall portion, and is in connection with at least one MRD, adapted for applying localized spectroscopy towards the media. MRD-based reactors, in which the MRD is at least partially inside the reactor or reaction media, and those in which the MRD accommodates the reactor, are also introduced. Lastly, the invention teaches an in situ method for controlling and analyzing of a reaction. The method comprises of providing an MRD-based reactor; applying a magnetic field within the reactor, especially for performing a plurality of localized spectroscopic measurements and either real time or offline analyzing and/or controlling of reactions in the flowing media.

0 8

Patent Number: 9,068,155

Grant date: December 31, 1969
Priority date: August 08, 2007
Estimated expiration date: August 08, 2027
Inventor(s): Allbritton; Nancy (Chapel Hill, NC), Sims; Christopher (Chapel Hill, NC), Wang; Yuli (Cary, NC), Shah; Pavak Kirit (Carrboro, NC)
Assignee(s): The University of North Carolina at Chapel Hill (Chapel Hill, NC)
External link: USPTO website

Abstract:

An apparatus for collecting or culturing cells or cell colonies includes: a common substrate formed from a flexible resilient polymeric material and having a plurality of wells formed therein; and a plurality of rigid cell carriers releasably connected to said common substrate, with said carriers arranged in the form of an array, and with each of the carriers resiliently received in one of the wells. A method of collecting or culturing cells or cell colonies with such an apparatus is carried out by depositing a liquid media carrying cells on the apparatus so that said cells settle on or adhere to said the carriers; and then (c) releasing at least one selected carrier having said cells thereon by gradual application of release energy to each carrier from the cavity in which it is received (e.g., by pushing with a probe).